Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2021; 12(2): 69-94
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.69
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
Mariana Miranda Sampaio, Maria Luísa Cordeiro Santos, Hanna Santos Marques, Vinícius Lima de Souza Gonçalves, Glauber Rocha Lima Araújo, Luana Weber Lopes, Jonathan Santos Apolonio, Camilo Santana Silva, Luana Kauany de Sá Santos, Beatriz Rocha Cuzzuol, Quézia Estéfani Silva Guimarães, Mariana Novaes Santos, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Márcio Vasconcelos Oliveira, Cláudio Lima Souza, Fabrício Freire de Melo
Mariana Miranda Sampaio, Maria Luísa Cordeiro Santos, Glauber Rocha Lima Araújo, Luana Weber Lopes, Jonathan Santos Apolonio, Camilo Santana Silva, Luana Kauany de Sá Santos, Beatriz Rocha Cuzzuol, Quézia Estéfani Silva Guimarães, Mariana Novaes Santos, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Márcio Vasconcelos Oliveira, Cláudio Lima Souza, Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
Hanna Santos Marques, Vinícius Lima de Souza Gonçalves, Campus Vitória da Conquista, Universidade Estadual do Sudoeste da Bahia, Vitória da Conquista 45083-900, Bahia, Brazil
Author contributions: All authors contributed equally to this paper with conception and design of the study, literature review and analysis, drafting, critical revision, editing, and providing final approval of the version to be published.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fabrício Freire de Melo, MSc, PhD, Postdoc, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Vitória da Conquista 45029-094, Bahia, Brazil. freiremelo@yahoo.com.br
Received: August 11, 2020
Peer-review started: August 11, 2020
First decision: December 11, 2020
Revised: December 22, 2020
Accepted: January 28, 2021
Article in press: January 28, 2021
Published online: February 24, 2021
Core Tip

Core Tip: Chronic myeloid leukemia is a clonal hematopoietic stem cell disorder with a well understood pathogenesis. In this sense, the research is directed towards new therapeutic alternatives and understanding of immunobiology, considering the growing resistance to standard therapy with tyrosine kinase inhibitors. This article aims to summarize the clinical approach and emerging therapeutic alternatives, considering the adverse effects of new drugs, transplants and immunotherapy.